As per senior official sources, the DCGI is actively taking action against manufacturing companies producing drugs that do not meet the required standards of quality (NSQ). This proactive approach aims to protect public health and maintain trust in the healthcare system.
Vadodara (Gujarat) [India], September 26: Visionary industrialist and leader Deepak C Mehta, Chairman and Managing Director of Deepak Nitrite Limited, has been conferred the prestigious Lifetime Achievement Award by the Indian Chemical Council (ICC) at the 59th ICC Annual Awards Function in
The second phase of polling in the Union Territory of Jammu and Kashmir concluded peacefully with 56.79 percent voter turnout across 26 assembly constituencies.
A voter turnout of 54.11 percent was recorded till 7 pm in the second phase of polling in the Union Territory of Jammu and Kashmir, as per the Election Commission of India.
The second phase of polling in the Union Territory of Jammu and Kashmir witnessed a voter turnout of 54 percent till 5 pm, as per the Election Commission of India.
A voter turnout of 46.12 percent was recorded till 3pm in the second phase of polling in six districts of the Union Territory of Jammu and Kashmir, according to the Election Commission of India.
Chief Election Commissioner Rajiv Kumar on Wednesday expressed his gratitude over a significant participation in the second phase of polling in Jammu and Kashmir and said that there is a history in the making.
The voter turnout in the second phase of voting for Jammu and Kashmir assembly elections was recorded at 36.93 per cent as of 1 pm on Wednesday, according to the Election Commission.
New Delhi [India], September 25: Further to our previous intimation dated 1st May 2024, regarding the strategic investment by New York Life Insurance Company ("NYL"), Max Estates Limited ("Max Estates") is pleased to announce the successful closure of the transaction with New York Life Insur
Ahmedabad (Gujarat) [India], September 25: Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of HETRONIFLY® (serplulimab, approve